HUTCHMED (LON:HCM) Share Price Crosses Above 200-Day Moving Average - What's Next?

Key Points

• HUTCHMED shares have crossed above their 200-day moving average of GBX 231.93, reaching a high of GBX 266 during trading.
• The company has a market capitalization of £2.23 billion and maintains a high P/E ratio of 490.57.
• HUTCHMED is recognized for its integrated R&D platform developing cancer drugs and has successfully marketed products in both China and the U.S.

HUTCHMED (China) Limited (LON:HCM - Get Free Report)'s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 231.93 ($3.14) and traded as high as GBX 266 ($3.61). HUTCHMED shares last traded at GBX 260 ($3.52), with a volume of 133,927 shares traded.

HUTCHMED Stock Performance

The company has a market cap of £2.27 billion, a PE ratio of 498.11 and a beta of 0.76. The business's 50-day moving average is GBX 244.09 and its 200 day moving average is GBX 231.64. The company has a debt-to-equity ratio of 11.97, a quick ratio of 2.97 and a current ratio of 2.81.

HUTCHMED Company Profile

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S. We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China. HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange's AIM market (Nasdaq/AIM:HCM; HKEX:13).